2025-520754-11-00CompletedPhase 1
Phase I, Open-Label Study to Evaluate the Pharmacokinetics, Safety and Tolerability of BIA 28-6156 in Participants with Varying Degrees of Renal Impairment
Source: EU CTIS (euclinicaltrials.eu) · Last updated 10 Dec 2025
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (actual)
- First submitted
- 22 May 2025
- Start date
- 25 Aug 2025
- Lead sponsor
- Bial R&D Investments S.A.
- Diseases
- Parkinson disease
- EU CT number
- 2025-520754-11-00
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 40
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CRU Hungary Kft. | Kistarcsa | Hungary | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.